Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Valuation

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Valuation & P/E History

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $19.67 with a market capitalization of $62.8 billion. This page provides historical valuation analysis for TAK based on 1279 data points covering 2021-09-14 to 2026-10-16...

TAK Valuation Metrics & Historical Range

The valuation table above shows Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether TAK is currently trading above or below its typical valuation levels.

• P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests TAK is expensively valued; below the median suggests it is cheap.
• P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
• EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock).
• FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.

Is TAK Overvalued or Undervalued?

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 50 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive TAK is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.

However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full TAK analysis page for a complete picture.

Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.TAK trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.